Pharma channel feed

Law pro­fes­sors call for FDA to dis­close all safe­ty and ef­fi­ca­cy da­ta for drugs

5 years ago
FDA+

Roche sees a slight dip in Q1 as biosim­i­lars keep bit­ing in­to block­buster on­col­o­gy tri­o's sales

5 years ago
Coronavirus

Bio­phar­ma ramps up lob­by­ing spend as drug pric­ing leg­is­la­tion nears

5 years ago

House De­moc­rats call on Emer­gent ex­ecs to tes­ti­fy on qual­i­ty is­sues next month

5 years ago
FDA+
Manufacturing

Bris­tol My­ers adds on at Cam­bridge Cross­ing, set­tling in even fur­ther in bustling Boston-area biotech hub

5 years ago

New Kaiser analy­sis shows how lim­it­ing price ne­go­ti­a­tions to tar­get­ed drugs may bet­ter fo­cus up­com­ing leg­is­la­tion

5 years ago
R&D

When is a drug re­al­ly a de­vice? Court knocks down FDA ap­peal in try­ing to sort that grey area

5 years ago
FDA+

As­traZeneca-Alex­ion merg­er slides through FTC re­view af­ter sup­posed M&A crack­down pos­es no bar­ri­ers

5 years ago
Deals

In high­ly un­usu­al move, Paci­ra sues med­ical jour­nal for li­bel over its non-opi­oid painkiller

5 years ago

Eli Lil­ly ax­es 163 Der­mi­ra staffers, shut­ters Men­lo Park site as it clos­es in around Dupix­ent ri­val le­brik­izum­ab

5 years ago
People

Up­dat­ed: Al­ny­lam faces DOJ probe over On­pat­tro mar­ket­ing

5 years ago

Janet Wood­cock on if the FDA is get­ting tougher on drug re­views: ‘I don’t think so’

5 years ago
FDA+

Fifth Cir­cuit sides with FTC in ma­jor pay-for-de­lay set­tle­ment case

5 years ago
FDA+

FDA dis­pens­es with in-per­son re­quire­ment for abor­tion pill ac­cess dur­ing the pan­dem­ic

5 years ago
FDA+

Re­gen­eron’s Covid mAb as a pro­phy­lac­tic in­jec­tion: Re­duced risk of symp­to­matic in­fec­tion by 81%

5 years ago
Coronavirus

AACR21: Eli Lil­ly blazes new trail for RET in­hibitor, gin­ning up a re­sponse in 9 sol­id tu­mor types in ear­ly da­ta

5 years ago
R&D

CBO: Con­gres­sion­al ac­tion on drug prices will make R&D spend­ing less at­trac­tive

5 years ago
FDA+

Bris­tol My­er­s' Op­di­vo notch­es a dou­ble win against chemo in esophageal can­cer, po­ten­tial­ly set­ting up 1st-line nod

5 years ago
R&D

Se­ries of JAK in­hibitor de­lays may sig­nal an up­com­ing FDA ad­comm

5 years ago
FDA+

Look­ing to re­bound from re­jec­tion in TNBC, Mer­ck­'s Keytru­da pass­es a new kid­ney can­cer test

5 years ago
R&D

For­mer In­di­v­ior med­ical lead who pled guilty to false opi­oid mar­ket­ing now seeks FDA hear­ing to es­cape de­bar­ment

5 years ago
FDA+

Re­call re­port: A-S pulls near­ly 200,000 ac­eta­minophen bot­tles off shelves; Apo­tex yanks AD­HD med

5 years ago
FDA+
Manufacturing

PDU­FA VII ne­go­ti­a­tions near fin­ish line with plans to re­vamp CBER and staff up

5 years ago
FDA+

Eye­ing stan­dard of care sta­tus in 3rd-line TNBC, Gilead nails down full OK for Trodelvy with a slight­ly broad­er la­bel

5 years ago
FDA+
First page Previous page 242243244245246247248 Next page Last page
A service from the Financial Times